Phaseline

Companies › Amryt Pharma

Amryt Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Metabolic and endocrine; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Metreleptin
Leptin receptor agonist
LEPRPhase 4Partial LipodystrophyFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06484868MetreleptinPhase 4Partial LipodystrophyMetabolic and endocrineFeb 2028

From the company's SEC filings

Complete response letters from FDA

Targets

LEPR (1)

Companies with the same targets

Regeneron Pharmaceuticals Chiesi Farmaceutici

Companies built like this

BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. Xintian Pharmaceutical Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Orphalan Lumos Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.